TGFB1 and neoplasm: In addition to CpG-ODNs, cancer immunotherapy has used GNPs in combination with TNF-α, TGF-β, the PDL1 inhibitor and TLR-7 agonist, specialized antibodies, and other tumor cell death factors or/and immunostimulants [123,136,137,138,139,140].